Sen. Shelley Moore Capito: Congress providing ‘wartime funding’ to defeat COVID-19
Get all the latest news on coronavirus and more delivered daily to your inbox. Sign up here.The stimulus package Congress is ...
Year: 2020
Top Five Trends For 2020
We’re just a few months into the new decade, and it’s abundantly clear that learning and development (L&D) will continue ...
Banana meal provides novel alternative in select aquaculture feeds
A team of researchers from multiple academic institutions in Brazil explored the use of banana meal in place of cornmeal ...
Connect Online with Crude Oil Tanker and Product Tanker Major Company Executives Get Expert Updates On Markets & Outlook
NEW YORK, March 25, 2020 (GLOBE NEWSWIRE) -- The digital forum is organized in partnership with Citi and in cooperation ...
Testing your product in real-world situations will help you discover consumer insights
Sean Bisceglia is the CEO of Curion, a leading provider of consumer insight research and product testing for both global ...
The Tim Cook Apple iPad prediction that’s looking increasingly blurry
Apple's new iPad Pro 2020.AppleIt would probably be wrong to argue semantics with Apple CEO Tim Cook, who said on ...
New Service From The Client Driven Practice Helps Financial Advisors Identify Client Communication Needs and Preferences During Times of Duress | News
PHILADELPHIA, March 25, 2020 /PRNewswire/ -- Every investment advisor is facing it: How to stay in contact with their clients ...
Food Tech Company Nature’s Fynd Secures $80 Million In Funding
Food tech company Nature’s Fynd (previously named Sustainable Bioproducts) announced it raised $80 million in funding Nature’s Fynd (previously named ...
Platinum based cancer drugs market size to reach US$1.8 billion by 2026
Selbyville, Delaware, March 25, 2020 (GLOBE NEWSWIRE) -- According to a new research report, the global platinum based cancer drugs ...
Neither first nor second biologic beneficial for many with JIA
Lianne Kearsley-Fleet Many patients with juvenile idiopathic arthritis see little benefit from treatment with their first or second biologic, according ...
